|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Aeglea Biotherapeutics, Inc. (AGLE) |
|
|
$0.60 0.00 (0.00%) as of 4:30 Thu 9/7
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
61,170,000 |
| Market
Cap: |
36.74(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.1064 - $0.6766 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aeglea BioTherapeutics is a holding company. Through its subsidiaries, Co. is a biotechnology company developing human enzyme therapeutics for people with rare metabolic diseases. Co.'s development programs include: Pegzilarginase in Arginase 1 Deficiency, which is a recombinant human Arginase 1 that enzymatically degrades the amino acid arginine and improves the stability and arginine-degrading activity of the enzyme in human plasma; and AGLE-177 in Homocystinuria, which is a PEGylated, or polyethylene glycol modified, human enzyme engineered to degrade free homocysteine and homocystine. Co.'s preclinical pipeline includes cystinuria program to reduce plasma cystine and cysteine levels.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
118,200 |
| Total Buy Value |
$0 |
$0 |
$0 |
$70,494 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
3,435,480 |
3,435,480 |
3,435,480 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
1 |
1 |
1 |
| Total Sell Transactions |
0 |
1 |
1 |
1 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Novartis Ag |
10% Owner |
– – • |
2016-04-12 |
4 |
B |
$10.00 |
$3,000,000 |
D/D |
300,000 |
2,310,924 |
2.45 |
- |
|
| Novartis Ag |
10% Owner |
– – • |
2016-04-12 |
4 |
A |
$0.00 |
$0 |
D/D |
2,010,924 |
2,010,924 |
|
- |
|
| York Charles N Ii |
Chief Financial Officer and VP |
• – – |
2016-04-12 |
4 |
A |
$0.00 |
$0 |
I/I |
11,560 |
11,560 |
|
- |
|
| York Charles N Ii |
Chief Financial Officer and VP |
• – – |
2016-04-12 |
4 |
A |
$0.00 |
$0 |
D/D |
1,324 |
8,828 |
|
- |
|
| Quinn Anthony |
Director |
– • – |
2016-04-12 |
4 |
B |
$10.00 |
$100,000 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
| Rowlinson Scott W |
VP, Research |
• – – |
2016-04-12 |
4 |
A |
$0.00 |
$0 |
I/I |
11,204 |
11,204 |
|
- |
|
| Tyler Joseph E |
VP, Manufacturing |
• – – |
2016-04-12 |
4 |
A |
$0.00 |
$0 |
D/D |
31,260 |
42,428 |
|
- |
|
| Lowe David George |
CEO and President |
• • – |
2016-04-12 |
4 |
A |
$0.00 |
$0 |
I/I |
5,658 |
5,658 |
|
- |
|
| Cox Russell J. |
Director |
– • – |
2016-04-12 |
4 |
B |
$10.00 |
$70,000 |
D/D |
7,000 |
7,000 |
2.39 |
- |
|
| Tyler Joseph E |
VP, ManufacturingOfficer |
• – – |
2016-04-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
11,168 |
|
- |
|
| York Charles N Ii |
Chief Financial Officer and VP |
• – – |
2016-04-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
7,504 |
|
- |
|
| Georgiou George |
Director |
– • – |
2016-04-06 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
270,476 |
|
- |
|
| Georgiou George |
Director |
– • – |
2016-04-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
138,528 |
|
- |
|
| Lowe David George |
CEO and PresidentOfficer |
• • – |
2016-04-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
206,382 |
|
- |
|
| Rowlinson Scott W |
VP, ResearchOfficer |
• – – |
2016-04-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
16,749 |
|
- |
|
| Torres S. Edward |
10% Owner |
– – • |
2016-04-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
57,619 |
|
- |
|
| Shanafelt Armen |
Director |
– • • |
2016-04-06 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
57,619 |
|
- |
|
92 Records found
|
|
Page 4 of 4 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
